Becton Dickinson Reports Q4 2026 Results with Strong EPS Growth and Increased Free Cash Flow
Becton Dickinson (BDX) reported strong fourth-quarter fiscal 2026 results, highlighted by a 27.3% year-over-year increase in adjusted diluted EPS to $4.15. Revenue reached $5.3 billion, representing 5.6% growth on a currency-neutral basis. Growth was driven by diverse segments including BioPharma Systems, which benefited from biologics and GLP-1 therapy demand, and Interventional revenue, bolstered by PureWick performance. The company demonstrated significant capital discipline, generating $2.9 billion in free cash flow for the full fiscal year—a 42% increase from the previous year. BDX also returned substantial value to shareholders through $1.2 billion in dividends and $2.4 billion in share repurchases. Looking ahead, the company provided FY27 adjusted EPS guidance of $13.10 to $13.30, while noting low single-digit revenue growth expectations due to Alaris capital comparison headwinds.
Tickers: $BDX
Topics: EPS Financial Guidance Free Cash Flow Revenue Growth